Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 11/20 | 0.92 |
| ▸ | GNAI3 | P08754 | 10/20 | 0.92 |
| ▸ | GNAI1 | P63096 | 10/20 | 0.92 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27389928 | 0.98 | GNAO1 (0.96) | GNAO1GNAI3GNAI1HRH4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5370724 | 0.96 | GNAO1 (1.00) | GNAO1GNAI3GNAI1HRH4ALDH1A1 | |
| Bromide SCHEMBL27708672 | 0.96 | GNAO1 (0.93) | GNAO1GNAI3GNAI1HRH4ALDH1A1 | |
| SCHEMBL4974361 | 0.94 | GNAO1 (0.81) | GNAO1GNAI3GNAI1HRH4TSHR | |
| SCHEMBL9214500 | 0.88 | GNAI3 (0.78) | GNAO1GNAI3GNAI1 | |
| SCHEMBL9214517 | 0.88 | GNAI3 (0.78) | GNAO1GNAI3GNAI1 | |
| SCHEMBL730717 | 0.85 | GNAI3 (0.68) | GNAO1GNAI3GNAI1HRH4SIGMAR1 | |
| SCHEMBL8665131 | 0.84 | GNAI3 (0.67) | GNAO1GNAI3GNAI1ALDH1A1TSHR | |
| Bromide SCHEMBL27689010 | 0.83 | GNAI3 (0.66) | GNAO1GNAI3GNAI1HRH4SIGMAR1 | |
| SCHEMBL28632179 | 0.82 | GNAI3 (0.70) | GNAO1GNAI3GNAI1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7651979-B2 | SUCH AS AMMINE (2-AMINO-3-PICOLINE) DICHLOROPLATINUM(II); EFFICIENCY AND SELECTIVITY FOR DESTROYING TRANSFORMED CELLS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-01-26 | — | — | US | claimed |
| EP-1778685-B1 | INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF | SANOL ARZNEI SCHWARZ GMBH (DE) | 2008-03-26 | — | — | EP | disclosed |
| US-20080051409-A1 | Indolizine Carboxamides and Aza and Diaza Derivatives Thereof | SCHWARZ PHARMA AG (DE) | 2008-02-28 | — | — | US | disclosed |
| US-20070299091-A1 | Azaindole Carboxamides | GMEINER PETER | 2007-12-27 | — | — | US | disclosed |
| EP-1778685-A1 | INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF | SCHWARZ PHARMA AG (DE) | 2007-05-02 | — | — | EP | disclosed |
| EP-1771448-A1 | AZAINDOLE CARBOXAMIDES | SCHWARZ PHARMA AG (DE) | 2007-04-11 | — | — | EP | disclosed |
| EP-1519726-B1 | UTILIZATION OF HETEROARENE CARBOXAMIDE AS DOPAMINE-D3 LIGANDS FOR THE TREATMENT OF CNS DISEASES | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-02-21 | — | — | EP | disclosed |
| EP-1749529-A1 | Utilisation of heteroarene carboxamide as dopamine-D3 ligands for the treatment of CNS diseases | SCHWARZ PHARMA AG (DE) | 2007-02-07 | — | — | EP | disclosed |
| EP-1733727-A1 | Ferrocenecarboxamide derivatives for use as dopamine D3 ligands for the treatment of CNS disorders | SCHWARZ PHARMA AG (DE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006050976-A1 | AZAINDOLE CARBOXAMIDES | SCHWARZ PHARMA AG (DE) | 2006-05-18 | — | — | WO | disclosed |
| EP-0723542-A4 | POLYMERIZABLE COMPOUNDS | HENKEL CORP (US) | 1996-10-23 | — | — | EP | disclosed |
| US-5565567-A | Polymerizable N,N'-substituted piperazine acrylamide compounds | HENKEL CORPORATION. (US) | 1996-10-15 | — | — | US | disclosed |
| US-5565567-A | Polymerizable N,N'-substituted piperazine acrylamide compounds | HENKEL CORPORATION. (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0723542-A1 | POLYMERIZABLE COMPOUNDS | HENKEL CORPORATION (US) | 1996-07-31 | — | — | EP | disclosed |
| EP-0723542-A1 | POLYMERIZABLE COMPOUNDS | HENKEL CORPORATION (US) | 1996-07-31 | — | — | EP | disclosed |
| CN-1126474-A | Polymerizable compounds | HENKEL CORP (US) | 1996-07-10 | — | — | CN | disclosed |
| WO-1994029296-A1 | POLYMERIZABLE COMPOUNDS | HENKEL CORPORATION (US) | 1994-12-22 | — | — | WO | disclosed |
| WO-1994029296-A1 | POLYMERIZABLE COMPOUNDS | HENKEL CORPORATION (US) | 1994-12-22 | — | — | WO | disclosed |
| US-5149815-A | Anticholirergic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-09-22 | — | — | US | disclosed |
| US-5093333-A | N-substituted-2-aminoquinolines useful for treating hypofunction of the cholinergic system | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299091-A1 | Azaindole Carboxamides | TPH1, TPH2, HTR1A | GNAO1 153/4885GNAI3 96/4885GNAI1 66/4885 |
| US-20080051409-A1 | Indolizine Carboxamides and Aza and Diaza Derivatives Thereof | GRIN2A, GRIN2C, GRIN1 | GNAO1 376/4885GNAI3 450/4885GNAI1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.